Last reviewed · How we verify

PCM/Oxy1

Maastricht University Medical Center · FDA-approved active Small molecule

PCM/Oxy1 is a fixed-dose combination of paracetamol (acetaminophen) and oxycodone that provides analgesia through dual mechanisms: paracetamol's antipyretic and analgesic effects via COX inhibition, and oxycodone's opioid receptor agonism for moderate to severe pain relief.

PCM/Oxy1 is a fixed-dose combination of paracetamol (acetaminophen) and oxycodone that provides analgesia through dual mechanisms: paracetamol's antipyretic and analgesic effects via COX inhibition, and oxycodone's opioid receptor agonism for moderate to severe pain relief. Used for Moderate to severe acute and chronic pain.

At a glance

Generic namePCM/Oxy1
SponsorMaastricht University Medical Center
Drug classOpioid analgesic combination
TargetMu opioid receptor (oxycodone); COX enzymes (paracetamol)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Paracetamol reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Oxycodone is a semi-synthetic opioid agonist that binds to mu, delta, and kappa opioid receptors in the central and peripheral nervous systems, enhancing pain relief. The combination allows for lower individual doses of each component while achieving effective analgesia for moderate to severe pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: